Pu C - Search Results

1

Enhancing therapeutic efficacy in homologous recombination-proficient pancreatic cancer via the combination of PARP1-PROTAC and a BRD4 inhibitor.

Pu C, Liu Y, Lan S, Fan H, Liu L, Liu J, Guo Y. Pu C, et al. Bioorg Med Chem. 2024 Dec 1;115:117970. doi: 10.1016/j.bmc.2024.117970. Epub 2024 Oct 26. Bioorg Med Chem. 2024. PMID: 39476572

2

Synthesis and biological evaluation of a tumor-selective degrader of PARP1.

Pu C, Wang S, Luo D, Liu Y, Ma X, Zhang H, Yu S, Lan S, Huang Q, Deng R, He X, Li R. Pu C, et al. Bioorg Med Chem. 2022 Sep 1;69:116908. doi: 10.1016/j.bmc.2022.116908. Epub 2022 Jun 26. Bioorg Med Chem. 2022. PMID: 35780655

3

Research progress of BRD4 in head and neck squamous cell carcinoma: Therapeutic application of novel strategies and mechanisms.

Tang J, Chen H, Fan H, Chen T, Pu C, Guo Y. Tang J, et al. Among authors: pu c. Bioorg Med Chem. 2024 Nov 1;113:117929. doi: 10.1016/j.bmc.2024.117929. Epub 2024 Sep 19. Bioorg Med Chem. 2024. PMID: 39317007 Review.

4

Discovery of a PROTAC targeting ALK with in vivo activity.

Yan G, Zhong X, Yue L, Pu C, Shan H, Lan S, Zhou M, Hou X, Yang J, Li R. Yan G, et al. Among authors: pu c. Eur J Med Chem. 2021 Feb 15;212:113150. doi: 10.1016/j.ejmech.2020.113150. Epub 2021 Jan 2. Eur J Med Chem. 2021. PMID: 33453602

5

Discovery of a novel covalent CDK4/6 inhibitor based on palbociclib scaffold.

Shan H, Ma X, Yan G, Luo M, Zhong X, Lan S, Yang J, Liu Y, Pu C, Tong Y, Li R. Shan H, et al. Among authors: pu c. Eur J Med Chem. 2021 Jul 5;219:113432. doi: 10.1016/j.ejmech.2021.113432. Epub 2021 Apr 3. Eur J Med Chem. 2021. PMID: 33857728

6

Selective degradation of PARP2 by PROTACs via recruiting DCAF16 for triple-negative breast cancer.

Pu C, Tong Y, Liu Y, Lan S, Wang S, Yan G, Zhang H, Luo D, Ma X, Yu S, Huang Q, Deng R, Li R. Pu C, et al. Eur J Med Chem. 2022 Jun 5;236:114321. doi: 10.1016/j.ejmech.2022.114321. Epub 2022 Apr 3. Eur J Med Chem. 2022. PMID: 35430559

7

Development of PROTAC degrader probe of CDK4/6 based on DCAF16.

Pu C, Liu Y, Deng R, Xu Q, Wang S, Zhang H, Luo D, Ma X, Tong Y, Li R. Pu C, et al. Bioorg Chem. 2023 Sep;138:106637. doi: 10.1016/j.bioorg.2023.106637. Epub 2023 May 27. Bioorg Chem. 2023. PMID: 37276679

8

Discovery of L15 as a novel Vif PROTAC degrader with antiviral activity against HIV-1.

Luo D, Luo R, Wang W, Deng R, Wang S, Ma X, Pu C, Liu Y, Zhang H, Yu S, Huang Q, Yang L, Tong Y, Zheng Y, Li R. Luo D, et al. Among authors: pu c. Bioorg Med Chem Lett. 2024 Oct 1;111:129880. doi: 10.1016/j.bmcl.2024.129880. Epub 2024 Jul 10. Bioorg Med Chem Lett. 2024. PMID: 38996941

9

Recent advances in dual PROTACs degrader strategies for disease treatment.

Liu J, Liu Y, Tang J, Gong Q, Yan G, Fan H, Zhang X, Pu C. Liu J, et al. Among authors: pu c. Eur J Med Chem. 2024 Dec 5;279:116901. doi: 10.1016/j.ejmech.2024.116901. Epub 2024 Sep 27. Eur J Med Chem. 2024. PMID: 39341095 Review.

10

Discovery of the GSH responsive "Y-PROTACs" targeting ALK and CDK4/6 as a potential treatment for cancer.

Wang S, Luo D, Pu C, Ma X, Zhang H, Feng Z, Deng R, Yu S, Liu Y, Huang Q, Li R. Wang S, et al. Among authors: pu c. Eur J Med Chem. 2023 Feb 15;248:115082. doi: 10.1016/j.ejmech.2022.115082. Epub 2023 Jan 1. Eur J Med Chem. 2023. PMID: 36628851

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

880 results

Search Page

Filters